SERPINE1 and metabolic syndrome: As PAI-1 expression is up-regulated in thrombotic and fibrotic diseases, PAI-1 inhibition has been used in the treatment of deep vein thrombosis, coronary syndrome (Schneiderman et al., 1992), metabolic syndrome (McGill et al., 1994), cancer (Yasar Yildiz et al., 2014) and type-2 diabetes (Gorlatova et al., 2007), as well as venous thromboembolism (Crowther et al., 2001).